- Home
- GOSS vs PRTA Comparison
GOSS vs PRTA Comparison
Compare GOSS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- PRTA
- Stock Information
- Founded
- GOSS 2015
- PRTA 2012
- Country
- GOSS United States
- PRTA Ireland
- Employees
- GOSS N/A
- PRTA N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- PRTA Health Care
- Exchange
- GOSS Nasdaq
- PRTA Nasdaq
- Market Cap
- GOSS 347.8M
- PRTA 472.1M
- IPO Year
- GOSS 2019
- PRTA N/A
- Fundamental
- Price
- GOSS $2.47
- PRTA $8.20
- Analyst Decision
- GOSS Strong Buy
- PRTA Buy
- Analyst Count
- GOSS 4
- PRTA 10
- Target Price
- GOSS $8.50
- PRTA $14.86
- AVG Volume (30 Days)
- GOSS 3.1M
- PRTA 1.2M
- Earning Date
- GOSS 08-05-2025
- PRTA 08-04-2025
- Dividend Yield
- GOSS N/A
- PRTA N/A
- EPS Growth
- GOSS N/A
- PRTA N/A
- EPS
- GOSS N/A
- PRTA N/A
- Revenue
- GOSS $40,237,000.00
- PRTA $10,341,000.00
- Revenue This Year
- GOSS N/A
- PRTA N/A
- Revenue Next Year
- GOSS $30.65
- PRTA $389.77
- P/E Ratio
- GOSS N/A
- PRTA N/A
- Revenue Growth
- GOSS N/A
- PRTA N/A
- 52 Week Low
- GOSS $0.66
- PRTA $4.32
- 52 Week High
- GOSS $2.65
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- PRTA 58.73
- Support Level
- GOSS $2.38
- PRTA $8.05
- Resistance Level
- GOSS $2.65
- PRTA $8.73
- Average True Range (ATR)
- GOSS 0.15
- PRTA 0.38
- MACD
- GOSS 0.03
- PRTA -0.05
- Stochastic Oscillator
- GOSS 76.67
- PRTA 47.62
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.